369 related articles for article (PubMed ID: 16224053)
1. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy.
Damås JK; Boullier A; Waehre T; Smith C; Sandberg WJ; Green S; Aukrust P; Quehenberger O
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2567-72. PubMed ID: 16224053
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in Wegener's granulomatosis--possible role in vascular inflammation.
Bjerkeli V; Damås JK; Fevang B; Holter JC; Aukrust P; Frøland SS
Rheumatology (Oxford); 2007 Sep; 46(9):1422-7. PubMed ID: 17616549
[TBL] [Abstract][Full Text] [Related]
3. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1).
Lucas AD; Bursill C; Guzik TJ; Sadowski J; Channon KM; Greaves DR
Circulation; 2003 Nov; 108(20):2498-504. PubMed ID: 14581400
[TBL] [Abstract][Full Text] [Related]
4. High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins.
Smith C; Halvorsen B; Otterdal K; Waehre T; Yndestad A; Fevang B; Sandberg WJ; Breland UM; Frøland SS; Oie E; Gullestad L; Damås JK; Aukrust P
Cardiovasc Res; 2008 Jul; 79(1):195-203. PubMed ID: 18339644
[TBL] [Abstract][Full Text] [Related]
5. Fractalkine and CX3CR1 are involved in the recruitment of intraepithelial lymphocytes of intrahepatic bile ducts.
Isse K; Harada K; Zen Y; Kamihira T; Shimoda S; Harada M; Nakanuma Y
Hepatology; 2005 Mar; 41(3):506-16. PubMed ID: 15726664
[TBL] [Abstract][Full Text] [Related]
6. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets.
Schulz C; Schäfer A; Stolla M; Kerstan S; Lorenz M; von Brühl ML; Schiemann M; Bauersachs J; Gloe T; Busch DH; Gawaz M; Massberg S
Circulation; 2007 Aug; 116(7):764-73. PubMed ID: 17679613
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of fractalkine/CX3CL1 and fractalkine receptor (CX3CR1) expression in abdominal aortic aneurysm disease.
Patel A; Jagadesham VP; Porter KE; Scott DJ; Carding SR
Eur J Vasc Endovasc Surg; 2008 Jul; 36(1):20-7. PubMed ID: 18296082
[TBL] [Abstract][Full Text] [Related]
8. Soluble interleukin-6 receptor alpha inhibits the cytokine-Induced fractalkine/CX3CL1 expression in human vascular endothelial cells in culture.
Matsumiya T; Imaizumi T; Fujimoto K; Cui X; Shibata T; Tamo W; Kumagai M; Tanji K; Yoshida H; Kimura H; Satoh K
Exp Cell Res; 2001 Sep; 269(1):35-41. PubMed ID: 11525637
[TBL] [Abstract][Full Text] [Related]
9. Expression of CX3C chemokine, fractalkine, and its receptor CX3CR1 in experimental autoimmune anterior uveitis.
Fang IM; Lin CP; Yang CM; Chen MS; Yang CH
Mol Vis; 2005 Jul; 11():443-51. PubMed ID: 16030495
[TBL] [Abstract][Full Text] [Related]
10. The CX3CL1-CX3CR1 system and psoriasis.
Plant D; Young HS; Watson RE; Worthington J; Griffiths CE
Exp Dermatol; 2006 Nov; 15(11):900-3. PubMed ID: 17002687
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors.
Waehre T; Yndestad A; Smith C; Haug T; Tunheim SH; Gullestad L; Frøland SS; Semb AG; Aukrust P; Damås JK
Circulation; 2004 Apr; 109(16):1966-72. PubMed ID: 15051633
[TBL] [Abstract][Full Text] [Related]
12. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS.
Hughes PM; Botham MS; Frentzel S; Mir A; Perry VH
Glia; 2002 Mar; 37(4):314-27. PubMed ID: 11870871
[TBL] [Abstract][Full Text] [Related]
13. Chemokines and common variable immunodeficiency; possible contribution of the fractalkine system (CX3CL1/CX3CR1) to chronic inflammation.
Fevang B; Yndestad A; Damås JK; Bjerkeli V; Ueland T; Holm AM; Beiske K; Aukrust P; Frøland SS
Clin Immunol; 2009 Feb; 130(2):151-61. PubMed ID: 18938112
[TBL] [Abstract][Full Text] [Related]
14. Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammation.
Smith C; Damås JK; Otterdal K; Øie E; Sandberg WJ; Yndestad A; Waehre T; Scholz H; Endresen K; Olofsson PS; Halvorsen B; Gullestad L; Frøland SS; Hansson GK; Aukrust P
J Am Coll Cardiol; 2006 Oct; 48(8):1591-9. PubMed ID: 17045893
[TBL] [Abstract][Full Text] [Related]
15. Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization.
Damås JK; Smith C; Øie E; Fevang B; Halvorsen B; Waehre T; Boullier A; Breland U; Yndestad A; Ovchinnikova O; Robertson AK; Sandberg WJ; Kjekshus J; Taskén K; Frøland SS; Gullestad L; Hansson GK; Quehenberger O; Aukrust P
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):614-20. PubMed ID: 17170367
[TBL] [Abstract][Full Text] [Related]
16. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in periodontal diseased tissue.
Hosokawa Y; Nakanishi T; Yamaguchi D; Nakae H; Matsuo T
Clin Exp Immunol; 2005 Mar; 139(3):506-12. PubMed ID: 15730397
[TBL] [Abstract][Full Text] [Related]
17. Fractalkine expression in the rhesus monkey brain during lentivirus infection and its control by 6-chloro-2',3'-dideoxyguanosine.
Depboylu C; Eiden LE; Schäfer MK; Reinhart TA; Mitsuya H; Schall TJ; Weihe E
J Neuropathol Exp Neurol; 2006 Dec; 65(12):1170-80. PubMed ID: 17146291
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease Phenotype.
Brand S; Hofbauer K; Dambacher J; Schnitzler F; Staudinger T; Pfennig S; Seiderer J; Tillack C; Konrad A; Göke B; Ochsenkühn T; Lohse P
Am J Gastroenterol; 2006 Jan; 101(1):99-106. PubMed ID: 16405540
[TBL] [Abstract][Full Text] [Related]
19. Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease.
Waehre T; Damås JK; Gullestad L; Holm AM; Pedersen TR; Arnesen KE; Torsvik H; Frøland SS; Semb AG; Aukrust P
J Am Coll Cardiol; 2003 May; 41(9):1460-7. PubMed ID: 12742282
[TBL] [Abstract][Full Text] [Related]
20. A potential role of the CXC chemokine GROalpha in atherosclerosis and plaque destabilization: downregulatory effects of statins.
Breland UM; Halvorsen B; Hol J; Øie E; Paulsson-Berne G; Yndestad A; Smith C; Otterdal K; Hedin U; Waehre T; Sandberg WJ; Frøland SS; Haraldsen G; Gullestad L; Damås JK; Hansson GK; Aukrust P
Arterioscler Thromb Vasc Biol; 2008 May; 28(5):1005-11. PubMed ID: 18276907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
